A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer

A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer

IntroductionSmall cell lung cancer (SCLC) accounts for 15% of all lung cancers and is characterized by high response rates to cytotoxic chemotherapy and equally high rates of relapse. Many resistance mechanisms have been proposed including resistance to doxorubicin via induction of a heat shock resp...

Full description

Bibliographic Details
Main Authors: Deepa S. Subramaniam, Stephen V. Liu, Jeanette Crawford, Jenna Kramer, Jillian Thompson, Hongkun Wang, Giuseppe Giaccone
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-03-01
Series:Frontiers in Oncology
Subjects:
small cell lung cancer
ganetespib
doxorubicin
Hsp90 inhibition
chemotherapy resistance
Online Access:http://journal.frontiersin.org/article/10.3389/fonc.2018.00064/full

Internet

http://journal.frontiersin.org/article/10.3389/fonc.2018.00064/full

Similar Items